DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The ISLAND Study: InSuLa Assessed Needs for Depression

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Depression

Intervention: Escitalopram (Drug); Cognitive Behavioral Therapy (Behavioral); Combination treatment (Escitalopram + CBT) (Other)

Phase: Phase 4

Status: Recruiting

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
Helen Mayberg, MD, Principal Investigator, Affiliation: Emory University
Boadie W Dunlop, MD/MS, Study Director, Affiliation: Emory University

Overall contact:
Tanja C Mletzko Crowe, MA, Phone: 404-712-5063, Email: tmletzk@emory.edu


While there are many effective options for treating a major depressive episode, there are no clinical markers that predict the likelihood of remission with an initial trial of either an antidepressant medication or psychotherapy. The goal of this study is to test how brain function changes in depress patients treated with cognitive behavioral therapy (CBT)

compared to patients treated with escitalopram ((s-CIT) - Lexapro®), an FDA approved

antidepressant. The study aims to determine if bran scan findings might help physicians to select the most effective antidepressant treatment for an individual patient. At total of 150 male and female outpatients who are between 21-55 years old will be enrolled. Participation in the study will last from 14-26 weeks. Subjects will be randomized to receive either escitalopram (s-CIT) or CBT for 12 weeks. Resting-state positron emission tomography (PET) and BOLD functional magnetic resonance imaging (fMRI) scans will be done before the treatment begins, and again at the end of treatment (week 12). Non-responders to s-cIT or CBT will be crossed over to receive an additional 12 weeks of treatment with the alternative intervention.

Clinical Details

Official title: Testing an Imaging Biomarker for Treatment Stratification in Major Depression

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Remission from major depressive episode

Secondary outcome: Response to treatment


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria: 1. Men or women aged 18-60 years. 2. Primary psychiatric diagnosis of Major Depressive Disorder, without psychotic features, confirmed via SCID-IV structured diagnostic interview. 3. Screening Hamilton Depression Rating Scale (HAMD) ≥ 18; and Baseline HAMD ≥ 15. 4. If the patient is a woman of child-bearing potential, she must agree to use an acceptable form of birth control for duration of study participation. 5. Able to understand and provide informed consent for participation. Exclusion Criteria: 1. Lifetime history of Bipolar Disorder, Dementia, Autism Spectrum Disorder, Schizophrenia, or any other Psychotic Disorder. 2. Psychotic symptoms occurring at any time during the current major depressive episode. 3. Current (past 12 months) diagnosis of Panic disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, Anorexia Nervosa, or Bulimia Nervosa. 4. Alcohol or Drug Dependence within 12 months or Abuse within 3 months (excluding nicotine and caffeine) of baseline visit, as assessed by history and urine drug screen. 5. Clinical evidence of a severe Personality Disorder, as assessed by the study psychiatrist, which would impede participation or completion of the trial. 6. Known neurological disorders or documented serious head injury. 7. Serious and unstable medical illnesses including cardiovascular disease and cancer. 8. Active medical conditions with known mood changes (endocrine, autoimmune disorders). 9. Current diabetes mellitus. 10. For women, pregnancy, lactation, or unwillingness to comply with birth control requirements. 11. Use of any of the following treatments or any other alternative therapy within 2 weeks of the pre-treatment PET scan that may have beneficial effects on mood, including St John's Wort, S-adenosyl methionine (SAMe), n-3 fatty acids, or light therapy. 12. Use of antidepressant medication within 1 month of the pre-treatment PET scan (within 5 weeks for fluoxetine and protryptyline). 13. Failure to achieve a much improved status (i. e. equivalent to >50% symptom reduction) with any lifetime treatment course of CBT (defined as a minimum of 4 sessions of a specified manual-driven therapy by a CBT-trained therapist) or escitalopram (defined as a minimum of 6 weeks of at least 10 mg/day). 14. Clinically significant active suicidal ideation or self-injurious behavior necessitating immediate treatment, as determined by the investigator. 15. Received electroconvulsive therapy in the past 6 months or during the current depressive episode. 16. Currently responding to medication treatment, without clinical reasons to change. 17. Current treatment with weekly individual or group psychotherapy of any type targeted at depressive symptoms. 18. QTc >500 milliseconds on EKG at screening. 19. Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control. 20. Use of concomitant medications with the exception of:

- Maintenance or prophylactic therapy for stable medical conditions.

- Hypnotic medication prescribed or approved by the study physician, (up to a

three doses per week) for insomnia, as long if not the night before a PET/MRI or clinic ratings visit. Antipsychotic medications, whether prescribed for sleep or other indications, are prohibited.

Locations and Contacts

Tanja C Mletzko Crowe, MA, Phone: 404-712-5063, Email: tmletzk@emory.edu

12 Executive Park Drive, 3rd floor, Atlanta, Georgia 30329, United States; Recruiting
Helen Mayberg, MD, Principal Investigator
Boadie W Dunlop, MD/MS, Sub-Investigator
W. Edward Craighead, PhD, Sub-Investigator
Additional Information

Study information

Starting date: September 2014
Last updated: March 3, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017